Dobrin Avramov Svinarov

Prof. Dobrin Avramov Svinarov


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Clinical Biochemistry
Verified
Journal Article
Closed access
MSMaria Shipkova
Maria Shipkova
DSDobrin Avramov Svinarov
Dobrin Avramov Svinarov

Verified
Journal Article
Open access
PDF file
Rumen Stefanov FilevRumen Stefanov Filev
Rumen Stefanov Filev
Lionel ROSTAINGLionel ROSTAING
Lionel ROSTAING
MLMila Lyubomirova
Mila Lyubomirova
BBBoris Iliev Bogov
Boris Iliev Bogov
KKKrasimir Kalinov
Krasimir Kalinov
DSDobrin Avramov Svinarov
Dobrin Avramov Svinarov
Regarding COVID-19 infection, Bulgaria has one of the lowest rates of vaccination in Europe, and its COVID-19-related mortality rate has been one of the highest in the European Union. Chronic kidney disease (CKD)-COVID-19 patients are at higher risk of developing acute kidney injury (AKI) and death after hospital admission. This single-center prospective cohort study from Bulgaria included 120 in-patient COVID-19 subjects of whom 70 had CKD and 50 normal renal function. Diabetes mellitus, hypertension, obesity, and cardiovascular disease were statistically more prevalent in the CKD group as compared to the non-CKD group. At admission, D-dimer, creatinine, and urea levels were significantly higher in the CKD group, whereas estimated glomerular-filtration rate was significantly lower as compared to the non-CKD patients. During hospitalization, 23 patients (19.1%) died, of which 19 were in the CKD group (p-value = 0.0096); in addition, 38 developed AKI (31.6%), of which 31 were in the CKD group (p-value = 0.0006). Using binary logistic regression, being male, having experienced AKI, and not having been treated with remdesivir were independent risk factors for COVID-19-induced mortality. Regarding risk of AKI, having had COVID-19-related symptoms for more than 6 days before admission, having CKD at baseline, and having not received remdesivir therapy were independent predictive factors for developing AKI after admission.
1

Verified
Journal Article
Open access
PDF file
Rumen Stefanov FilevRumen Stefanov Filev
Rumen Stefanov Filev
MLMila Lyubomirova
Mila Lyubomirova
BBBoris Iliev Bogov
Boris Iliev Bogov
KKKrasimir Kalinov
Krasimir Kalinov
Julieta HristovaJulieta Hristova
Julieta Hristova
Lionel ROSTAINGLionel ROSTAING
Lionel ROSTAING
In this prospective study, we assessed biomarkers of inflammation (IL-6 and SAA) from the serum of 120 COVID-19 patients, of whom 70 had chronic kidney disease. All the samples were taken at emergency-department (ED) admission. Our goal was to relate the biomarkers to the results of death and acute kidney injury. All the patients underwent chest computer tomography to estimate the severity score (0–5), which was performed at hospital admission. Finally, biomarkers were also evaluated in a healthy control group and in non-COVID-19-CKD patients. IL-6 and SAA were statistically different between the subgroups, i.e., they were significantly increased in patients with COVID-19. Both of the biomarkers (IL-6 and SAA) were independently associated with mortality, AKI and a higher grade of pathological changes in the lung’s parenchyma. Both high baseline levels of IL-6 and SAA on hospital admission were highly correlated with a later ventilatory requirement and mortality, independent of hospital stay. Mortality was found to be significantly higher when the chest CT severity score was 3–4, compared with a severity score of 0–2 (p < 0.0001). Conclusions: at the admission stage, IL-6 and SAA are useful markers for COVID-19 patients with CKD.

5 June 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Rumen Stefanov FilevRumen Stefanov Filev
Rumen Stefanov Filev
MLMila Lyubomirova
Mila Lyubomirova
BBBoris Iliev Bogov
Boris Iliev Bogov
KKKrasimir Kalinov
Krasimir Kalinov
Julieta HristovaJulieta Hristova
Julieta Hristova
Lionel ROSTAINGLionel ROSTAING
Lionel ROSTAING
Post-acute sequelae of SARS-CoV-2 (PASC) is a significant health concern, particularly for patients with chronic kidney disease (CKD). This study investigates the long-term outcomes of individuals with CKD who were infected with COVID-19, focusing on their health status over a three-year period post-infection. Data were collected from both CKD and non-CKD patients who survived SARS-CoV-2 infection and were followed for three years as part of a research study on the impact, prognosis, and consequences of COVID-19 infection in CKD patients. In this prospective cohort study, we analyzed clinical records, laboratory findings, and patient-reported outcomes assessed at intervals during follow-up. The results indicated no permanent changes in renal function in any of the groups analyzed, although patients without CKD exhibited faster recovery over time. Furthermore, we examined the effect of RAAS-blocker therapy over time, finding no influence on PASC symptoms or renal function recovery. Regarding PASC symptoms, most patients recovered within a short period, but some required prolonged follow-up and specialized post-recovery management. Following up with patients in the post-COVID-19 period is crucial, as there is still insufficient information and evidence regarding the long-term effects, particularly in relation to CKD.

14 October 2021 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
SWSteven H. Wong
Steven H. Wong
PMPierre Marquet
Pierre Marquet
DCDario Cattaneo
Dario Cattaneo
DSDobrin Avramov Svinarov
Dobrin Avramov Svinarov
SBStein Bergan
Stein Bergan
MSMaria Shipkova
Maria Shipkova
An abstract is unavailable. This article is available as a PDF only.

2 December 2022 in Medicine
Verified
Journal Article
Open access
Rumen Stefanov FilevRumen Stefanov Filev
Rumen Stefanov Filev
Lionel ROSTAINGLionel ROSTAING
Lionel ROSTAING
MLMila Lyubomirova
Mila Lyubomirova
BBBoris Iliev Bogov
Boris Iliev Bogov
KKKrasimir Kalinov
Krasimir Kalinov
DSDobrin Avramov Svinarov
Dobrin Avramov Svinarov
When angiotensin-converting enzyme inhibitor/angiotensin receptor blocker-treated patients present with SARS-CoV-2 infection there is a debate to know whether renin-angiotensin-aldosterone (RAAS) blockers should be stopped or not. We conducted a prospective observational study in Bulgarian COVID-19-infected patients with or without chronic kidney disease (CKD) to assess whether maintenance RAAS blocker therapy has an impact on SARS-CoV-2 infection and its complications. We included 120 in-patient COVID-19 subjects, of whom 70 had CKD and 50 had normal renal function. A total of 30% of the patients (total number of 36 patients, 21 females) were receiving RAAS therapy at admission and it was maintained throughout hospitalization. The overall mortality was 19.2% (23 patients); there was no significant difference across the 2 groups (P-value = .21), except in RAAS blockers-treated hypertensive patients who had a significantly lower mortality as compared to non-RAAS-blockers-treated hypertensive patients (P = .04). Regarding subsequent intensive-care unit admission, there were 50% less patients in the RAAS group (4 out of 36, i.e., 11%) as compared to 19 out of 84 from the non-RAAS group, that is, 22.6% (P = .29). Overall, 37 patients developed acute kidney injury (any stage by KDIGO); of them 14 (37.8%) were receiving RAAS blockers. Acute kidney injury was not significantly associated with the use of RAAS blockers (P-value = .28). Likewise, both in non-CKD and in CKD patients the use of RAAS blockers did not have an impact on renal function recovery after SARS-CoV-2 infection. Finally, regarding RAAS blockers and the biological parameters outcome only D-dimers were significantly lower at the follow-up as compared to that in non-RAAS blocker treated patients. RAAS blockers benefited patients with hypertension by lowering mortality rate. Other than that, RAAS blocker therapy continuation during SARS-CoV-2 infection in CKD and non-CKD patients had no significant impact upon major outcomes.